NCT02107846已完成2 期
A Phase 2a, Open-Label, Sequential Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 (Plant Recombinant Human Glucocerebrosidase) in Enzyme Replacement Therapy-Naïve Subjects With Gaucher Disease
Protalix1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2014年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Area under the curve
研究概览
简要总结
This is an open-label, dose escalation study to evaluate the safety of oral PRX-112 and pharmacokinetics of GCD in subjects with Gaucher disease naive to enzyme replacement therapy. The dose levels of PRX-112 are 50 units, 100 units, 200 units and 400 units GCD. Subjects will receive once daily oral administrations of PRX-112 for 5 consecutive days at each dose level with a 2-day washout period between doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female age 18 or older
- •Historical diagnosis of Gaucher disease by low leukocyte GCD activity level
- •Haemoglobin ≥ 10 g/dL
- •Body mass index (BMI) of 18 kg/m2-30 kg/m2 inclusive
- •Subject is able to provide written informed consent
- •Female subjects of child bearing potential must not be pregnant or lactating with a negative urine pregnancy test result at the screening visit.
- •Female subjects of child-bearing potential and male subjects with female partners of childbearing potential must use two methods of contraception at all times during the study, one of which must be a barrier method. Acceptable methods of contraception are oral contraceptives, barrier methods (male condom, female condom, diaphragm, cervical cap, spermicide or intrauterine device), surgical sterility (documented doctor's report of vasectomy, hysterectomy and/or bilateral oophorectomy) and/or postmenopausal status (defined as at least 1 year without menses as demonstrated by medical history or subject report).
- •Negative laboratory tests for HIV, HBsAg and HCV at the screening visit
- •Naïve to any previous ERT or have received the last ERT treatment 12 months before signing IC
排除标准
- •Presence of a gastrointestinal (GI) disease affecting motility or absorption
- •Subjects with any history of allergic response to biological drugs or other allergies deemed clinically significant by the Investigator
- •Reported history of alcohol or drug abuse
- •Subject has donated blood in the 3 months prior to screening or subject has received plasma derivatives in the 6 months prior to screening
- •Use of any investigational drug or participation in another clinical trial in the 3 months prior to screening (subject report)
- •Subjects who have previously received ERT with positive anti-human plant recombinant GCD (prGCD) antibodies
- •Clinical evidence of any active significant disease that could potentially compromise the ability of the Investigator to evaluate or interpret the effects of the study treatment on safety assessment, thus increasing the risk to the subject to unacceptable levels
- •Presence of any medical, emotional, behavioural or psychological condition that, in the judgement of the Investigator, would interfere the compliance requirements of the study
- •Subject has used any medication (excluding acetaminophen or dyprione) within 7 days of screening, including laxatives, teas and food additives known to be used for the treatment of constipation or diarrhea
研究组 & 干预措施
50 Units
Experimental
PRX-112 50 Units daily for 5 days
干预措施: PRX-112 (Drug)
100 Units
Experimental
PRX-112 100 Units daily for 5 days
干预措施: PRX-112 (Drug)
200 Units
Experimental
PRX-112 200 Units daily for 5 days
干预措施: PRX-112 (Drug)
400 Units
Experimental
PRX-112 400 Units daily for 5 days
干预措施: PRX-112 (Drug)
结局指标
主要结局
Area under the curve
时间窗: 24 hours
Blood samples for GCD level every 2 hours for 24 hours
Adverse Events
时间窗: 7 Days
Reporting of adverse events collected daily
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Phase 2 Pharmacokinetics Study of TLC590 for Postsurgical Pain Management in Multiple Surgical ModelsPostsurgical Pain ManagementNCT06574269TLC Biopharmaceuticals, Inc.120
进行中（未招募）
2 期
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)Congenital HyperinsulinismNCT04732416Hanmi Pharmaceutical Company Limited17
招募中
2 期
Allogenic Hepatocyte Transplantation Into Periduodenal Lymph NodesEnd Stage Liver DiseaseNCT04496479LyGenesis, Inc.12
已完成
2 期
Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) AmyloidosisTTR-mediated AmyloidosisNCT01617967Alnylam Pharmaceuticals29
招募中
1 期
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderB-cell MalignancyNon-Hodgkin LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMarginal Zone LymphomaDLBCL UnclassifiableRichter's TransformationMantle Cell LymphomaFollicular LymphomaWaldenström MacroglobulinemiaNCT05294731BeiGene146